A condition of an abnormally low level of PHOSPHATES in the blood.
An inherited condition of abnormally low serum levels of PHOSPHATES (below 1 mg/liter) which can occur in a number of genetic diseases with defective reabsorption of inorganic phosphorus by the PROXIMAL RENAL TUBULES. This leads to phosphaturia, HYPOPHOSPHATEMIA, and disturbances of cellular and organ functions such as those in X-LINKED HYPOPHOSPHATEMIC RICKETS; OSTEOMALACIA; and FANCONI SYNDROME.
A hereditary disorder characterized by HYPOPHOSPHATEMIA; RICKETS; OSTEOMALACIA; renal defects in phosphate reabsorption and vitamin D metabolism; and growth retardation. Autosomal and X-linked dominant and recessive variants have been reported.
A membrane-bound metalloendopeptidase that may play a role in the degradation or activation of a variety of PEPTIDE HORMONES and INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS. Genetic mutations that result in loss of function of this protein are a cause of HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT.
Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis.
Inorganic salts of phosphoric acid.
Genetic diseases that are linked to gene mutations on the X CHROMOSOME in humans (X CHROMOSOME, HUMAN) or the X CHROMOSOME in other species. Included here are animal models of human X-linked diseases.
A non-electrogenic sodium-dependent phosphate transporter. It is found primarily in apical membranes of PROXIMAL RENAL TUBULES.
Disorders caused by interruption of BONE MINERALIZATION manifesting as OSTEOMALACIA in adults and characteristic deformities in infancy and childhood due to disturbances in normal BONE FORMATION. The mineralization process may be interrupted by disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis, resulting from dietary deficiencies, or acquired, or inherited metabolic, or hormonal disturbances.
A family of small polypeptide growth factors that share several common features including a strong affinity for HEPARIN, and a central barrel-shaped core region of 140 amino acids that is highly homologous between family members. Although originally studied as proteins that stimulate the growth of fibroblasts this distinction is no longer a requirement for membership in the fibroblast growth factor family.
A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.
An electrogenic sodium-dependent phosphate transporter. It is present primarily in BRUSH BORDER membranes of PROXIMAL RENAL TUBULES.
Neoplasms composed of connective tissue, including elastic, mucous, reticular, osseous, and cartilaginous tissue. The concept does not refer to neoplasms located in connective tissue.
Excretion of abnormally high level of CALCIUM in the URINE, greater than 4 mg/kg/day.
A condition of metabolic imbalance that is caused by complications of initially feeding a severely malnourished patient too aggressively. Usually occurring within the first 5 days of refeeding, this syndrome is characterized by WATER-ELECTROLYTE IMBALANCE; GLUCOSE INTOLERANCE; CARDIAC ARRHYTHMIAS; and DIARRHEA.
A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.
A family of sodium-phosphate cotransporter proteins with eight transmembrane domains. They are present primarily in the KIDNEY and SMALL INTESTINE and are responsible for renal and small intestinal epithelial transport of phosphate.
The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.
A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.
A family of symporters that facilitate sodium-dependent membrane transport of phosphate.
A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
A state due to excess loss of carbon dioxide from the body. (Dorland, 27th ed)
A hereditary or acquired form of generalized dysfunction of the PROXIMAL KIDNEY TUBULE without primary involvement of the KIDNEY GLOMERULUS. It is usually characterized by the tubular wasting of nutrients and salts (GLUCOSE; AMINO ACIDS; PHOSPHATES; and BICARBONATES) resulting in HYPOKALEMIA; ACIDOSIS; HYPERCALCIURIA; and PROTEINURIA.
Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)
Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.
A mitochondrial cytochrome P450 enzyme that catalyzes the 1-alpha-hydroxylation of 25-hydroxyvitamin D3 (also known as 25-hydroxycholecalciferol) in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP27B1 gene, converts 25-hydroxyvitamin D3 to 1-alpha,25-dihydroxyvitamin D3 which is the active form of VITAMIN D in regulating bone growth and calcium metabolism. This enzyme is also active on plant 25-hydroxyvitamin D2 (ergocalciferol).
Glucuronidase is an enzyme (specifically, a glycosidase) that catalyzes the hydrolysis of glucuronic acid from various substrates, playing crucial roles in metabolic processes like detoxification and biotransformation within organisms.
Mature osteoblasts that have become embedded in the BONE MATRIX. They occupy a small cavity, called lacuna, in the matrix and are connected to adjacent osteocytes via protoplasmic projections called canaliculi.
A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE.
Phosphorus used in foods or obtained from food. This element is a major intracellular component which plays an important role in many biochemical pathways relating to normal physiological functions. High concentrations of dietary phosphorus can cause nephrocalcinosis which is associated with impaired kidney function. Low concentrations of dietary phosphorus cause an increase in calcitriol in the blood and osteoporosis.
Abnormally high level of calcium in the blood.
Disorders in the processing of phosphorus in the body: its absorption, transport, storage, and utilization.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
A disease of pregnant and lactating cows and ewes leading to generalized paresis and death. The disease, which is characterized by hypocalcemia, occurs at or shortly after parturition in cows and within weeks before or after parturition in ewes.
A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.
Formation of stones in the KIDNEY.
Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.
A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.
New World marsupials of the family Didelphidae. Opossums are omnivorous, largely nocturnal and arboreal MAMMALS, grow to about three feet in length, including the scaly prehensile tail, and have an abdominal pouch in which the young are carried at birth.
Process by which organic tissue becomes hardened by the physiologic deposit of calcium salts.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
The delivery of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously, or by some other non-alimentary route. The basic components of TPN solutions are protein hydrolysates or free amino acid mixtures, monosaccharides, and electrolytes. Components are selected for their ability to reverse catabolism, promote anabolism, and build structural proteins.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.

X-linked hypophosphataemia: a homologous disorder in humans and mice. (1/178)

X-linked hypophosphatemia is an inherited disorder of phosphate (Pi) homeostasis characterized by growth retardation, rickets and osteomalacia, hypophosphataemia, and aberrant renal Pi reabsorption and vitamin D metabolism. Studies in murine Hyp and Gy homologues have identified a specific defect in Na+-Pi cotransport at the brush border membrane, abnormal regulation of 1,25-dihydroxyvitamin D3 (1,25(OH)2D) synthesis and degradation, and an intrinsic defect in bone mineralization. The mutant gene has been identified in XLH patients, by positional cloning, and in Hyp and Gy mice, and was designated PHEX/Phex to signify a PHosphate-regulating gene with homology to Endopeptidases on the X chromosome. PHEX/Phex is expressed in bones and teeth but not in kidney and efforts are under way to elucidate how loss of PHEX/Phex function elicits the mutant phenotype. Based on its homology to endopeptidases, it is postulated that PHEX/Phex is involved in the activation or inactivation of a peptide hormone(s) which plays a key role in the regulation of bone mineralization, renal Pi handling and vitamin D metabolism.  (+info)

Protein-RNA interactions determine the stability of the renal NaPi-2 cotransporter mRNA and its translation in hypophosphatemic rats. (2/178)

Hypophosphatemia leads to an increase in type II Na(+)-dependent inorganic phosphate cotransporter (NaPi-2) mRNA and protein levels in the kidney and increases renal phosphate reabsorption. Nuclear transcript run-on experiments showed that the effect of a low phosphate diet was post-transcriptional. In an in vitro degradation assay, renal proteins from hypophosphatemic rats stabilized the NaPi-2 transcript 6-fold compared with control rats and this was dependent upon an intact NaPi-2 3'-untranslated region (UTR). To determine an effect of hypophosphatemia upon NaPi-2 protein synthesis, the incorporation of injected [(35)S]methionine into renal proteins was studied in vivo. Hypophosphatemia led to increased [(35)S]methionine incorporation only into NaPi-2 protein. The effect of hypophosphatemia on translation was studied in an in vitro translation assay, where hypophosphatemic renal proteins led to increased translation of NaPi-2 and other transcripts. NaPi-2 RNA interaction with cytosolic proteins was studied by UV cross-linking and Northwestern gels. Hypophosphatemic proteins led to increased binding of renal cytosolic proteins to the 5'-UTR of NaPi-2 mRNA. Therefore, hypophosphatemia increases NaPi-2 gene expression post-transcriptionally, which correlates with a more stable transcript mediated by the 3'-UTR, and an increase in NaPi-2 translation involving protein binding to the 5'-UTR. These findings show that phosphate regulates gene expression by affecting protein-RNA interactions in vivo.  (+info)

PHEX gene and hypophosphatemia. (3/178)

PHEX gene and hypophosphatemia. X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) are diseases that have in common abnormal proximal renal tubular function resulting in increased renal clearance of inorganic phosphorus and hypophosphatemia. The recent discovery of the PHEX gene has provided new insights to these disorders. In this regard, identification of the PHEX gene product as a membrane-bound endopeptidase suggests that the pathophysiologic cascade underlying XLH likely involves inactivation mutations of the gene causing a failure to clear an active hormone, phosphatonin, from the circulation. The presence of this hormone through unknown mechanisms decreases the sodium-dependent phosphate cotransporter in the kidney, resulting in impaired phosphate transport. In contrast, TIO likely evolves secondary to tumor overproduction of the putative phosphatonin, which exerts physiologic function despite efforts to counteract the resultant hypophosphatemia with overproduction of PHEX transcripts that are insufficient to accommodate the enhanced substrate load. These potential pathophysiologic mechanisms for XLH and TIO provide valuable inroads to understanding phosphate homeostasis, as well as vitamin D metabolism, bone mineralization, and calcium metabolism.  (+info)

Persistent, progressive hypophosphataemia after voluntary hyperventilation. (4/178)

Hyperventilation (HV) and respiratory alkalosis are associated with hypophosphataemia, although the extent and duration of HV required to produce changes in serum phosphate levels are not known. We sought to characterize the effects of HV, with or without dextrose loading, on serum phosphate levels and other biochemical parameters. HV was monitored by controlling the end-tidal partial pressure of carbon dioxide (PETCO(2)). The effect of dextrose was studied because infusion of a glucose load is known to promote a fall in serum phosphate via stimulation of glycolysis. Eight healthy volunteers were enrolled in four study protocols: (1) HV for 20 min to a PETCO(2) of 25-30 mmHg (mild); (2) HV for 20 min to a PETCO(2) of 15-20 mmHg (severe); (3) mild HV with intravenous dextrose loading, and (4) dextrose loading alone. Periodic measurements of serum phosphate, venous pH, serum 2,3-diphosphoglycerate (2,3-DPG) and other parameters were made. Serum phosphate fell during HV and continued to decline after cessation of HV. Dextrose loading alone caused a fall in serum phosphate that continued for at least 30 min after cessation of the infusion (P<0.0002). HV combined with dextrose resulted in a greater decline in serum phosphate than either variable alone (P=0.003). The maximal decline in serum phosphate occurred in severe HV, with a mean decrease of 0.38 mmol/l at 20 min after cessation of HV (P<0.0001). Serum phosphate was still significantly lowered compared with baseline at 90 min after cessation of HV (P=0.001). Other significant changes seen with HV included a decrease in serum glucose (P<0.01), a decrease in serum potassium (P<0.05) and an increase in venous pH (P<0.007). Serum 2, 3-DPG levels did not change significantly in any study protocol. Thus relatively mild acute HV produces significant changes in serum phosphate. In both mild and severe HV this effect is progressive after cessation of HV. This phenomenon has not been shown before, and may have significant clinical implications.  (+info)

Severe hypophosphatemia during hematopoietic reconstitution after allogeneic peripheral blood stem cell transplantation. (5/178)

A patient suffering from acute myeloid leukemia (FAB M5a) received a PBSC allograft from a matched, related donor. On day 13 after transplantation severe hypophosphatemia (0.21 mmol/l) was first noted which persisted irrespective of intravenous phosphate administration, and within 2 days reached concentrations below 0.13 mmol/l. After repeated phosphate substitution serum phosphate returned to 1.40 mmol/l on day 17. Phosphate in urine, and calcium in serum were recorded as unchanged throughout. Clinical signs and symptoms due to severe hypophosphatemia were not observed except for paresthesia in the lower extremities. The precipitous fall in serum phosphate coincided with hematopoietic reconstitution as reflected by a steep rise in leukocyte count from 0.08 x 109/l on day 10 to 5. 94 x 109/l on day 15 after transplantation. Thus, isolated hypophosphatemia was likely the result of excessive cellular phosphate uptake during hematopoietic reconstitution. Electrolyte monitoring after PBSCT should include serum phosphate to identify the hypophosphatemia associated with hematopoietic recovery.  (+info)

Reflex sympathetic dystrophy in hypophosphataemic osteomalacia with femoral neck fracture: a case report. (6/178)

We report a male patient who presented with suspicion of skeletal metastases based upon an abnormal 99-mTc bone scan, which showed increased uptake at both femoral heads, left femoral neck, and several ribs. The images also suggested reflex sympathetic dystrophy, subcapital fracture of the left femur, and rib fractures. A diagnosis of hypophosphataemic osteomalacia was finally made.  (+info)

Recognition and management of hungry bone syndrome--a case report. (7/178)

Hungry bone syndrome (HBS) following successful parathyroid surgery is a well described phenomenon. However, few studies have clearly addressed this syndrome or looked at the outcome of perioperative management. We report a case of HBS following successful parathyroid surgery. The perioperative management is discussed and literature pertaining to this interesting case is reviewed.  (+info)

Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression. (8/178)

BACKGROUND: Impaired phosphate handling of the renal allograft is a common problem and of multifactorial origin. The aim of the study was to elucidate whether a rapamycin- or a mycophenolate-based immunosuppressive therapy aggravates the renal phosphate leak in kidney transplant recipients. METHODS: Renal phosphate handling was determined in thirty-eight cadaveric allograft recipients, with good renal function at 8, 12, 20 and 28 weeks after transplantation. Nineteen patients (group 1) received triple immunosuppression with rapamycin, cyclosporine and prednisolone, nineteen other transplant recipients received mycophenolate mofetil, cyclosporine and prednisolone immunosuppression (group 2), and six healthy subjects (group 3) served as controls. After 12 weeks of stable graft function, group 1 patients were divided further into two subgroups. Ten patients were kept on their immunosuppressive regimen (group 1A), whereas the remaining nine randomly chosen subjects had their cyclosporine withdrawn; they were thus maintained on a dual immunosuppression regimen with prednisolone and a higher dosage of rapamycin (group 1B). RESULTS: Renal phosphate reabsorption was significantly lower in group 1 at 8 and 12 weeks after transplantation as compared with groups 2 and 3. At 20 weeks after transplantation, patients with rapamycin-based immunosuppression (groups 1A and 1B) continued to exhibit hypophosphataemia and impaired renal phosphate handling. Group 1B had the lowest TmP/ GFR compared with all groups. At 28 weeks, renal phosphate reabsorption and plasma phosphate levels were no longer different between patient groups and controls. CONCLUSION: These data suggest that rapamycin-based immunosuppression prolongs the phosphate leak of the allografted kidney, leading to low serum phosphate levels during the first weeks after transplantation.  (+info)

Hypophosphatemia is a medical condition characterized by abnormally low levels of phosphate (phosphorus) in the blood, specifically below 2.5 mg/dL. Phosphate is an essential electrolyte that plays a crucial role in various bodily functions such as energy production, bone formation, and maintaining acid-base balance.

Hypophosphatemia can result from several factors, including malnutrition, vitamin D deficiency, alcoholism, hormonal imbalances, and certain medications. Symptoms of hypophosphatemia may include muscle weakness, fatigue, bone pain, confusion, and respiratory failure in severe cases. Treatment typically involves correcting the underlying cause and administering phosphate supplements to restore normal levels.

Familial Hypophosphatemia is a genetic disorder characterized by low levels of phosphate in the blood (hypophosphatemia) due to impaired absorption of phosphates in the gut. This condition results from mutations in the SLC34A3 gene, which provides instructions for making a protein called NaPi-IIc, responsible for reabsorbing phosphates from the filtrate in the kidney tubules back into the bloodstream.

In familial hypophosphatemia, the impaired function of NaPi-IIc leads to excessive loss of phosphate through urine, resulting in hypophosphatemia. This condition can cause rickets (a softening and weakening of bones) in children and osteomalacia (softening of bones) in adults. Symptoms may include bowed legs, bone pain, muscle weakness, and short stature.

Familial Hypophosphatemia is inherited as an autosomal recessive trait, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop the condition.

Familial Hypophosphatemic Rickets (FHR) is a genetic disorder characterized by impaired reabsorption of phosphate in the kidneys, leading to low levels of phosphate in the blood (hypophosphatemia). This condition results in defective mineralization of bones and teeth, causing rickets in children and osteomalacia in adults.

FHR is typically caused by mutations in the PHEX gene, which encodes a protein that helps regulate phosphate levels in the body. In FHR, the mutation leads to an overproduction of a hormone called fibroblast growth factor 23 (FGF23), which increases phosphate excretion in the urine and decreases the activation of vitamin D, further contributing to hypophosphatemia.

Symptoms of FHR may include bowing of the legs, bone pain, muscle weakness, short stature, dental abnormalities, and skeletal deformities. Treatment typically involves oral phosphate supplements and active forms of vitamin D to correct the hypophosphatemia and improve bone mineralization. Regular monitoring of blood phosphate levels, kidney function, and bone health is essential for effective management of this condition.

PHEX (Phosphate Regulating Endopeptidase Homolog, X-Linked) is a gene that encodes for an enzyme called phosphate regulating neutral endopeptidase. This enzyme is primarily expressed in osteoblasts, which are cells responsible for bone formation.

The main function of the PHEX protein is to regulate the levels of a hormone called fibroblast growth factor 23 (FGF23) by breaking it down. FGF23 plays an essential role in maintaining phosphate homeostasis by regulating its reabsorption in the kidneys and its absorption from the gut.

Inactivating mutations in the PHEX gene can lead to X-linked hypophosphatemia (XLH), a genetic disorder characterized by low levels of phosphate in the blood, impaired bone mineralization, and rickets. In XLH, the production of FGF23 is increased due to the lack of regulation by PHEX, leading to excessive excretion of phosphate in the urine and decreased absorption from the gut. This results in hypophosphatemia, impaired bone mineralization, and other skeletal abnormalities.

Osteomalacia is a medical condition characterized by the softening of bones due to defective bone mineralization, resulting from inadequate vitamin D, phosphate, or calcium. It mainly affects adults and is different from rickets, which occurs in children. The primary symptom is bone pain, but muscle weakness can also occur. Prolonged osteomalacia may lead to skeletal deformities and an increased risk of fractures. Treatment typically involves supplementation with vitamin D, calcium, and sometimes phosphate.

Phosphates, in a medical context, refer to the salts or esters of phosphoric acid. Phosphates play crucial roles in various biological processes within the human body. They are essential components of bones and teeth, where they combine with calcium to form hydroxyapatite crystals. Phosphates also participate in energy transfer reactions as phosphate groups attached to adenosine diphosphate (ADP) and adenosine triphosphate (ATP). Additionally, they contribute to buffer systems that help maintain normal pH levels in the body.

Abnormal levels of phosphates in the blood can indicate certain medical conditions. High phosphate levels (hyperphosphatemia) may be associated with kidney dysfunction, hyperparathyroidism, or excessive intake of phosphate-containing products. Low phosphate levels (hypophosphatemia) might result from malnutrition, vitamin D deficiency, or certain diseases affecting the small intestine or kidneys. Both hypophosphatemia and hyperphosphatemia can have significant impacts on various organ systems and may require medical intervention.

X-linked genetic diseases refer to a group of disorders caused by mutations in genes located on the X chromosome. These conditions primarily affect males since they have only one X chromosome and therefore don't have a second normal copy of the gene to compensate for the mutated one. Females, who have two X chromosomes, are typically less affected because they usually have one normal copy of the gene on their other X chromosome.

Examples of X-linked genetic diseases include Duchenne and Becker muscular dystrophy, hemophilia A and B, color blindness, and fragile X syndrome. Symptoms and severity can vary widely depending on the specific condition and the nature of the genetic mutation involved. Treatment options depend on the particular disease but may include physical therapy, medication, or in some cases, gene therapy.

Sodium-phosphate cotransporter proteins, type IIc (NPTIIc), are a subtype of sodium-dependent phosphate transporters that play a crucial role in the regulation of phosphate homeostasis within the body. They are located primarily in the kidney's proximal tubule cells and intestinal epithelial cells.

NPTIIc proteins facilitate the active transport of inorganic phosphate (Pi) ions across the cell membrane, in conjunction with sodium ions (Na+). This symport mechanism allows for the movement of Pi against its concentration gradient, from areas of low concentration to high concentration. The energy required for this process is derived from the electrochemical gradient of sodium ions.

These transporters are essential for maintaining normal phosphate levels in the body, as they help reabsorb a significant portion of filtered phosphate in the kidneys and absorb dietary phosphate in the intestines. Dysregulation of NPTIIc proteins can lead to various disorders related to phosphate homeostasis, such as hypophosphatemia (low serum phosphate levels) or hyperphosphatemia (high serum phosphate levels), which can have detrimental effects on bone health, mineral metabolism, and overall body function.

Rickets is a medical condition characterized by the softening and weakening of bones in children, primarily caused by deficiency of vitamin D, calcium, or phosphate. It leads to skeletal deformities, bone pain, and growth retardation. Prolonged lack of sunlight exposure, inadequate intake of vitamin D-rich foods, or impaired absorption or utilization of vitamin D can contribute to the development of rickets.

Fibroblast Growth Factors (FGFs) are a family of growth factors that play crucial roles in various biological processes, including cell survival, proliferation, migration, and differentiation. They bind to specific tyrosine kinase receptors (FGFRs) on the cell surface, leading to intracellular signaling cascades that regulate gene expression and downstream cellular responses. FGFs are involved in embryonic development, tissue repair, and angiogenesis (the formation of new blood vessels). There are at least 22 distinct FGFs identified in humans, each with unique functions and patterns of expression. Some FGFs, like FGF1 and FGF2, have mitogenic effects on fibroblasts and other cell types, while others, such as FGF7 and FGF10, are essential for epithelial-mesenchymal interactions during organ development. Dysregulation of FGF signaling has been implicated in various pathological conditions, including cancer, fibrosis, and developmental disorders.

Phosphorus is an essential mineral that is required by every cell in the body for normal functioning. It is a key component of several important biomolecules, including adenosine triphosphate (ATP), which is the primary source of energy for cells, and deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), which are the genetic materials in cells.

Phosphorus is also a major constituent of bones and teeth, where it combines with calcium to provide strength and structure. In addition, phosphorus plays a critical role in various metabolic processes, including energy production, nerve impulse transmission, and pH regulation.

The medical definition of phosphorus refers to the chemical element with the atomic number 15 and the symbol P. It is a highly reactive non-metal that exists in several forms, including white phosphorus, red phosphorus, and black phosphorus. In the body, phosphorus is primarily found in the form of organic compounds, such as phospholipids, phosphoproteins, and nucleic acids.

Abnormal levels of phosphorus in the body can lead to various health problems. For example, high levels of phosphorus (hyperphosphatemia) can occur in patients with kidney disease or those who consume large amounts of phosphorus-rich foods, and can contribute to the development of calcification of soft tissues and cardiovascular disease. On the other hand, low levels of phosphorus (hypophosphatemia) can occur in patients with malnutrition, vitamin D deficiency, or alcoholism, and can lead to muscle weakness, bone pain, and an increased risk of infection.

Sodium-phosphate cotransporter proteins, type IIa (NaPi-IIa), are a subtype of membrane transport proteins that facilitate the active transport of sodium and phosphate ions across the cell membrane. They play a crucial role in maintaining phosphate homeostasis within the body by regulating the reabsorption of phosphate in the kidney's proximal tubules.

NaPi-IIa proteins are located on the brush border membrane of the proximal tubule cells and function to couple the movement of sodium ions down its electrochemical gradient into the cell with the influx of phosphate ions against its concentration gradient, from the lumen into the cell. This process is driven by the sodium-potassium ATPase pump, which maintains a low intracellular sodium concentration and a negative membrane potential.

NaPi-IIa proteins are encoded by the SLC34A1 gene in humans and are subject to regulation by various hormonal and physiological factors, such as parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and dietary phosphate intake. Dysregulation of NaPi-IIa function has been implicated in several kidney diseases and disorders of phosphate homeostasis, such as hyperphosphatemia and hypophosphatemic rickets.

Neoplasms of connective tissue are abnormal growths or tumors that develop from the cells that form the body's supportive framework, including bones, cartilage, tendons, ligaments, and other connective tissues. These neoplasms can be benign (non-cancerous) or malignant (cancerous), and they can cause various symptoms depending on their location and size.

There are several types of connective tissue neoplasms, including:

1. Fibroma: A benign tumor that arises from fibrous connective tissue.
2. Fibrosarcoma: A malignant tumor that develops from fibrous connective tissue.
3. Lipoma: A benign tumor that arises from fat cells.
4. Liposarcoma: A malignant tumor that develops from fat cells.
5. Chondroma: A benign tumor that arises from cartilage.
6. Chondrosarcoma: A malignant tumor that develops from cartilage.
7. Osteoma: A benign tumor that arises from bone.
8. Osteosarcoma: A malignant tumor that develops from bone.
9. Giant cell tumors: Benign or malignant tumors that contain many giant cells, which are large, multinucleated cells.
10. Synovial sarcoma: A malignant tumor that arises from the synovial tissue that lines joints and tendons.

Connective tissue neoplasms can cause various symptoms depending on their location and size. For example, a benign lipoma may cause a painless lump under the skin, while a malignant osteosarcoma may cause bone pain, swelling, and fractures. Treatment options for connective tissue neoplasms include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Hypercalciuria is a medical condition characterized by an excessive amount of calcium in the urine. It can occur when the body absorbs too much calcium from food, or when the bones release more calcium than usual. In some cases, it may be caused by certain medications, kidney disorders, or genetic factors.

Hypercalciuria can increase the risk of developing kidney stones and other kidney problems. It is often diagnosed through a 24-hour urine collection test that measures the amount of calcium in the urine. Treatment may include changes in diet, increased fluid intake, and medications to help reduce the amount of calcium in the urine.

Refeeding syndrome is a potentially fatal shift in fluid and electrolyte balance that may occur in malnourished individuals when they begin to receive nutrition. This occurs due to significant metabolic changes, including increased insulin secretion, which leads to shifts of fluids and electrolytes from the extracellular to intracellular space.

This shift can result in hypophosphatemia (low phosphate levels), hypokalemia (low potassium levels), hypomagnesemia (low magnesium levels), and fluid overload, which can cause serious complications such as heart failure, seizures, and even death if not properly managed. It's important to monitor and correct electrolyte imbalances and fluid status during refeeding to prevent these complications.

Parathyroid hormone (PTH) is a polypeptide hormone that plays a crucial role in the regulation of calcium and phosphate levels in the body. It is produced and secreted by the parathyroid glands, which are four small endocrine glands located on the back surface of the thyroid gland.

The primary function of PTH is to maintain normal calcium levels in the blood by increasing calcium absorption from the gut, mobilizing calcium from bones, and decreasing calcium excretion by the kidneys. PTH also increases phosphate excretion by the kidneys, which helps to lower serum phosphate levels.

In addition to its role in calcium and phosphate homeostasis, PTH has been shown to have anabolic effects on bone tissue, stimulating bone formation and preventing bone loss. However, chronic elevations in PTH levels can lead to excessive bone resorption and osteoporosis.

Overall, Parathyroid Hormone is a critical hormone that helps maintain mineral homeostasis and supports healthy bone metabolism.

Sodium-phosphate cotransporter proteins, type II (NPTII), are a group of membrane transport proteins that facilitate the active transport of inorganic phosphate (Pi) and sodium ions (Na+) across the cell membrane. They play a crucial role in maintaining intracellular phosphate homeostasis and regulating various physiological processes, including energy metabolism, signal transduction, and bone mineralization.

The type II sodium-phosphate cotransporters are further divided into three subtypes: NPT2a, NPT2b, and NPT2c. These subtypes differ in their tissue distribution, substrate affinity, and regulatory mechanisms. NPT2a is primarily expressed in the kidney proximal tubules and plays a major role in reabsorbing phosphate from the glomerular filtrate. NPT2b is predominantly found in the small intestine and contributes to phosphate absorption from the diet. NPT2c is widely distributed, with significant expression in the kidney, brain, and testis, although its specific functions are not as well understood as those of NPT2a and NPT2b.

Dysregulation of sodium-phosphate cotransporter proteins, type II, has been implicated in several pathological conditions, such as renal phosphate wasting disorders, tumoral calcinosis, and certain forms of hyperparathyroidism.

Calcitriol is the active form of vitamin D, also known as 1,25-dihydroxyvitamin D. It is a steroid hormone that plays a crucial role in regulating calcium and phosphate levels in the body to maintain healthy bones. Calcitriol is produced in the kidneys from its precursor, calcidiol (25-hydroxyvitamin D), which is derived from dietary sources or synthesized in the skin upon exposure to sunlight.

Calcitriol promotes calcium absorption in the intestines, helps regulate calcium and phosphate levels in the kidneys, and stimulates bone cells (osteoblasts) to form new bone tissue while inhibiting the activity of osteoclasts, which resorb bone. This hormone is essential for normal bone mineralization and growth, as well as for preventing hypocalcemia (low calcium levels).

In addition to its role in bone health, calcitriol has various other physiological functions, including modulating immune responses, cell proliferation, differentiation, and apoptosis. Calcitriol deficiency or resistance can lead to conditions such as rickets in children and osteomalacia or osteoporosis in adults.

Mesenchymoma is a very rare type of tumor that contains a mixture of different types of mesenchymal tissues, such as muscle, fat, bone, cartilage, or fibrous tissue. It typically occurs in children and young adults, and can be found in various parts of the body, including the head, neck, retroperitoneum (the area behind the abdominal cavity), and the limbs.

Mesenchymomas are usually slow-growing and may not cause any symptoms until they reach a large size. Treatment typically involves surgical removal of the tumor, but radiation therapy or chemotherapy may also be used in some cases. The prognosis for mesenchymoma depends on several factors, including the location and size of the tumor, the patient's age and overall health, and the specific types of tissue that are present in the tumor.

Paraneoplastic syndromes refer to a group of rare disorders that are caused by an abnormal immune system response to a cancerous (malignant) tumor. These syndromes are characterized by symptoms or signs that do not result directly from the growth of the tumor itself, but rather from substances produced by the tumor or the body's immune system in response to the tumor.

Paraneoplastic syndromes can affect various organs and systems in the body, including the nervous system, endocrine system, skin, and joints. Examples of paraneoplastic syndromes include Lambert-Eaton myasthenic syndrome (LEMS), which affects nerve function and causes muscle weakness; cerebellar degeneration, which can cause difficulty with coordination and balance; and dermatomyositis, which is an inflammatory condition that affects the skin and muscles.

Paraneoplastic syndromes can occur in association with a variety of different types of cancer, including lung cancer, breast cancer, ovarian cancer, and lymphoma. Treatment typically involves addressing the underlying cancer, as well as managing the symptoms of the paraneoplastic syndrome.

Sodium-phosphate cotransporter proteins are membrane transport proteins that facilitate the active transport of sodium and inorganic phosphate ions across biological membranes. These proteins play a crucial role in maintaining phosphate homeostasis within the body by regulating the absorption and excretion of phosphate in the kidneys and intestines. They exist in two major types, type I (NaPi-I) and type II (NaPi-II), each having multiple subtypes with distinct tissue distributions and regulatory mechanisms.

Type I sodium-phosphate cotransporters are primarily expressed in the kidney's proximal tubules and play a significant role in reabsorbing phosphate from the primary urine back into the bloodstream. Type II sodium-phosphate cotransporters, on the other hand, are found in both the kidneys and intestines. In the kidneys, they contribute to phosphate reabsorption, while in the intestines, they facilitate phosphate absorption from food.

These proteins function by coupling the passive downhill movement of sodium ions (driven by the electrochemical gradient) with the active uphill transport of phosphate ions against their concentration gradient. This coupled transport process enables cells to maintain intracellular phosphate concentrations within a narrow range, despite fluctuations in dietary intake and renal function.

Dysregulation of sodium-phosphate cotransporter proteins has been implicated in various pathological conditions, such as chronic kidney disease (CKD), tumoral calcinosis, and certain genetic disorders affecting phosphate homeostasis.

Hyperphosphatemia is a medical condition characterized by an excessively high level of phosphate (a form of the chemical element phosphorus) in the blood. Phosphate is an important component of various biological molecules, such as DNA, RNA, and ATP, and it plays a crucial role in many cellular processes, including energy metabolism and signal transduction.

In healthy individuals, the concentration of phosphate in the blood is tightly regulated within a narrow range to maintain normal physiological functions. However, when the phosphate level rises above this range (typically defined as a serum phosphate level greater than 4.5 mg/dL or 1.46 mmol/L), it can lead to hyperphosphatemia.

Hyperphosphatemia can result from various underlying medical conditions, including:

* Kidney dysfunction: The kidneys are responsible for filtering excess phosphate out of the blood and excreting it in the urine. When the kidneys fail to function properly, they may be unable to remove enough phosphate, leading to its accumulation in the blood.
* Hypoparathyroidism: The parathyroid glands produce a hormone called parathyroid hormone (PTH), which helps regulate calcium and phosphate levels in the body. In hypoparathyroidism, the production of PTH is insufficient, leading to an increase in phosphate levels.
* Hyperparathyroidism: In contrast, excessive production of PTH can also lead to hyperphosphatemia by increasing the release of phosphate from bones and decreasing its reabsorption in the kidneys.
* Excessive intake of phosphate-rich foods or supplements: Consuming large amounts of phosphate-rich foods, such as dairy products, nuts, and legumes, or taking phosphate supplements can raise blood phosphate levels.
* Tumor lysis syndrome: This is a complication that can occur after the treatment of certain types of cancer, particularly hematological malignancies. The rapid destruction of cancer cells releases large amounts of intracellular contents, including phosphate, into the bloodstream, leading to hyperphosphatemia.
* Rhabdomyolysis: This is a condition in which muscle tissue breaks down, releasing its contents, including phosphate, into the bloodstream. It can be caused by various factors, such as trauma, infection, or drug toxicity.

Hyperphosphatemia can have several adverse effects on the body, including calcification of soft tissues, kidney damage, and metabolic disturbances. Therefore, it is essential to diagnose and manage hyperphosphatemia promptly to prevent complications. Treatment options may include dietary modifications, medications that bind phosphate in the gastrointestinal tract, and dialysis in severe cases.

Respiratory alkalosis is a medical condition that occurs when there is an excess base (bicarbonate) and/or a decrease in carbon dioxide in the body. This leads to an increase in pH level of the blood, making it more alkaline than normal. Respiratory alkalosis is usually caused by conditions that result in hyperventilation, such as anxiety, lung disease, or high altitude. It can also be caused by certain medications and medical procedures. Symptoms of respiratory alkalosis may include lightheadedness, confusion, and tingling in the fingers and toes. Treatment typically involves addressing the underlying cause of the condition.

Fanconi syndrome is a medical condition that affects the proximal tubules of the kidneys. These tubules are responsible for reabsorbing various substances, such as glucose, amino acids, and electrolytes, back into the bloodstream after they have been filtered through the kidneys.

In Fanconi syndrome, there is a defect in the reabsorption process, causing these substances to be lost in the urine instead. This can lead to a variety of symptoms, including:

* Polyuria (excessive urination)
* Polydipsia (excessive thirst)
* Dehydration
* Metabolic acidosis (an imbalance of acid and base in the body)
* Hypokalemia (low potassium levels)
* Hypophosphatemia (low phosphate levels)
* Vitamin D deficiency
* Rickets (softening and weakening of bones in children) or osteomalacia (softening of bones in adults)

Fanconi syndrome can be caused by a variety of underlying conditions, including genetic disorders, kidney diseases, drug toxicity, and heavy metal poisoning. Treatment typically involves addressing the underlying cause, as well as managing symptoms such as electrolyte imbalances and acid-base disturbances.

Hypocalcemia is a medical condition characterized by an abnormally low level of calcium in the blood. Calcium is a vital mineral that plays a crucial role in various bodily functions, including muscle contraction, nerve impulse transmission, and bone formation. Normal calcium levels in the blood usually range from 8.5 to 10.2 milligrams per deciliter (mg/dL). Hypocalcemia is typically defined as a serum calcium level below 8.5 mg/dL or, when adjusted for albumin (a protein that binds to calcium), below 8.4 mg/dL (ionized calcium).

Hypocalcemia can result from several factors, such as vitamin D deficiency, hypoparathyroidism (underactive parathyroid glands), kidney dysfunction, certain medications, and severe magnesium deficiency. Symptoms of hypocalcemia may include numbness or tingling in the fingers, toes, or lips; muscle cramps or spasms; seizures; and, in severe cases, cognitive impairment or cardiac arrhythmias. Treatment typically involves correcting the underlying cause and administering calcium and vitamin D supplements to restore normal calcium levels in the blood.

Rhabdomyolysis is a medical condition characterized by the breakdown and degeneration of skeletal muscle fibers, leading to the release of their intracellular contents into the bloodstream. This can result in various complications, including electrolyte imbalances, kidney injury or failure, and potentially life-threatening conditions if not promptly diagnosed and treated.

The process of rhabdomyolysis typically involves three key components:

1. Muscle injury: Direct trauma, excessive exertion, prolonged immobilization, infections, metabolic disorders, toxins, or medications can cause muscle damage, leading to the release of intracellular components into the bloodstream.
2. Release of muscle contents: When muscle fibers break down, they release various substances, such as myoglobin, creatine kinase (CK), lactate dehydrogenase (LDH), aldolase, and potassium ions. Myoglobin is a protein that can cause kidney damage when present in high concentrations in the bloodstream, particularly when it is filtered through the kidneys and deposits in the renal tubules.
3. Systemic effects: The release of muscle contents into the bloodstream can lead to various systemic complications, such as electrolyte imbalances (particularly hyperkalemia), acidosis, hypocalcemia, and kidney injury or failure due to myoglobin-induced tubular damage.

Symptoms of rhabdomyolysis can vary widely depending on the severity and extent of muscle damage but may include muscle pain, weakness, swelling, stiffness, dark urine, and tea-colored or cola-colored urine due to myoglobinuria. In severe cases, patients may experience symptoms related to kidney failure, such as nausea, vomiting, fatigue, and decreased urine output.

Diagnosis of rhabdomyolysis typically involves measuring blood levels of muscle enzymes (such as CK and LDH) and evaluating renal function through blood tests and urinalysis. Treatment generally focuses on addressing the underlying cause of muscle damage, maintaining fluid balance, correcting electrolyte imbalances, and preventing or managing kidney injury.

25-Hydroxyvitamin D3 1-alpha-Hydroxylase is an enzyme that is responsible for converting 25-hydroxyvitamin D3 (a precursor form of vitamin D) to its active form, 1,25-dihydroxyvitamin D3. This activation process occurs primarily in the kidneys and is tightly regulated by various factors such as calcium levels, parathyroid hormone, and vitamin D status.

The activated form of vitamin D, 1,25-dihydroxyvitamin D3, plays a crucial role in maintaining calcium homeostasis by increasing the absorption of calcium from the gut and promoting bone health. It also has various other functions, including modulation of immune function, cell growth regulation, and protection against cancer.

Deficiencies in 25-Hydroxyvitamin D3 1-alpha-Hydroxylase can lead to vitamin D deficiency and its associated symptoms, such as osteomalacia (softening of the bones) and osteoporosis (brittle bones). Conversely, overactivity of this enzyme can result in hypercalcemia (elevated levels of calcium in the blood), which can cause a range of symptoms including kidney stones, abdominal pain, nausea, and vomiting.

Glucuronidase is an enzyme that catalyzes the hydrolysis of glucuronic acid from various substrates, including molecules that have been conjugated with glucuronic acid as part of the detoxification process in the body. This enzyme plays a role in the breakdown and elimination of certain drugs, toxins, and endogenous compounds, such as bilirubin. It is found in various tissues and organisms, including humans, bacteria, and insects. In clinical contexts, glucuronidase activity may be measured to assess liver function or to identify the presence of certain bacterial infections.

Osteocytes are the most abundant cell type in mature bone tissue. They are star-shaped cells that are located inside the mineralized matrix of bones, with their processes extending into small spaces called lacunae and canaliculi. Osteocytes are derived from osteoblasts, which are bone-forming cells that become trapped within the matrix they produce.

Osteocytes play a crucial role in maintaining bone homeostasis by regulating bone remodeling, sensing mechanical stress, and modulating mineralization. They communicate with each other and with osteoblasts and osteoclasts (bone-resorbing cells) through a network of interconnected processes and via the release of signaling molecules. Osteocytes can also respond to changes in their environment, such as hormonal signals or mechanical loading, by altering their gene expression and releasing factors that regulate bone metabolism.

Dysfunction of osteocytes has been implicated in various bone diseases, including osteoporosis, osteogenesis imperfecta, and Paget's disease of bone.

Vitamin D is a fat-soluble secosteroid that is crucial for the regulation of calcium and phosphate levels in the body, which are essential for maintaining healthy bones and teeth. It can be synthesized by the human body when skin is exposed to ultraviolet-B (UVB) rays from sunlight, or it can be obtained through dietary sources such as fatty fish, fortified dairy products, and supplements. There are two major forms of vitamin D: vitamin D2 (ergocalciferol), which is found in some plants and fungi, and vitamin D3 (cholecalciferol), which is produced in the skin or obtained from animal-derived foods. Both forms need to undergo two hydroxylations in the body to become biologically active as calcitriol (1,25-dihydroxyvitamin D3), the hormonally active form of vitamin D. This activated form exerts its effects by binding to the vitamin D receptor (VDR) found in various tissues, including the small intestine, bone, kidney, and immune cells, thereby influencing numerous physiological processes such as calcium homeostasis, bone metabolism, cell growth, and immune function.

Dietary Phosphorus is a mineral that is an essential nutrient for human health. It is required for the growth, maintenance, and repair of body tissues, including bones and teeth. Phosphorus is also necessary for the production of energy, the formation of DNA and RNA, and the regulation of various physiological processes.

In the diet, phosphorus is primarily found in protein-containing foods such as meat, poultry, fish, dairy products, legumes, and nuts. It can also be found in processed foods that contain additives such as phosphoric acid, which is used to enhance flavor or as a preservative.

The recommended daily intake of phosphorus for adults is 700 milligrams (mg) per day. However, it's important to note that excessive intake of phosphorus, particularly from supplements and fortified foods, can lead to health problems such as kidney damage and calcification of soft tissues. Therefore, it's recommended to obtain phosphorus primarily from whole foods rather than supplements.

Hypercalcemia is a medical condition characterized by an excess of calcium ( Ca2+ ) in the blood. While the normal range for serum calcium levels is typically between 8.5 to 10.2 mg/dL (milligrams per deciliter) or 2.14 to 2.55 mmol/L (millimoles per liter), hypercalcemia is generally defined as a serum calcium level greater than 10.5 mg/dL or 2.6 mmol/L.

Hypercalcemia can result from various underlying medical disorders, including primary hyperparathyroidism, malignancy (cancer), certain medications, granulomatous diseases, and excessive vitamin D intake or production. Symptoms of hypercalcemia may include fatigue, weakness, confusion, memory loss, depression, constipation, nausea, vomiting, increased thirst, frequent urination, bone pain, and kidney stones. Severe or prolonged hypercalcemia can lead to serious complications such as kidney failure, cardiac arrhythmias, and calcification of soft tissues. Treatment depends on the underlying cause and severity of the condition.

Phosphorus metabolism disorders refer to a group of conditions that affect the body's ability to properly regulate the levels and utilization of phosphorus. Phosphorus is an essential mineral that plays a critical role in many biological processes, including energy production, bone formation, and nerve function.

Disorders of phosphorus metabolism can result from genetic defects, kidney dysfunction, vitamin D deficiency, or other medical conditions. These disorders can lead to abnormal levels of phosphorus in the blood, which can cause a range of symptoms, including muscle weakness, bone pain, seizures, and respiratory failure.

Examples of phosphorus metabolism disorders include:

1. Hypophosphatemia: This is a condition characterized by low levels of phosphorus in the blood. It can be caused by various factors, such as malnutrition, vitamin D deficiency, and kidney dysfunction.
2. Hyperphosphatemia: This is a condition characterized by high levels of phosphorus in the blood. It can be caused by kidney failure, tumor lysis syndrome, and certain medications.
3. Hereditary hypophosphatemic rickets: This is a genetic disorder that affects the body's ability to regulate vitamin D and phosphorus metabolism. It can lead to weakened bones and skeletal deformities.
4. Oncogenic osteomalacia: This is a rare condition that occurs when tumors produce substances that interfere with phosphorus metabolism, leading to bone pain and weakness.

Treatment for phosphorus metabolism disorders depends on the underlying cause of the disorder and may include dietary changes, supplements, medications, or surgery.

"Bone" is the hard, dense connective tissue that makes up the skeleton of vertebrate animals. It provides support and protection for the body's internal organs, and serves as a attachment site for muscles, tendons, and ligaments. Bone is composed of cells called osteoblasts and osteoclasts, which are responsible for bone formation and resorption, respectively, and an extracellular matrix made up of collagen fibers and mineral crystals.

Bones can be classified into two main types: compact bone and spongy bone. Compact bone is dense and hard, and makes up the outer layer of all bones and the shafts of long bones. Spongy bone is less dense and contains large spaces, and makes up the ends of long bones and the interior of flat and irregular bones.

The human body has 206 bones in total. They can be further classified into five categories based on their shape: long bones, short bones, flat bones, irregular bones, and sesamoid bones.

Parturient paresis, also known as Eclampsia or Puerperal eclampsia, is a serious condition that can occur during pregnancy or after childbirth. It is characterized by the onset of seizures (convulsions) and coma in a woman who has previously developed high blood pressure and proteinuria (protein in the urine) – a condition known as preeclampsia.

Eclampsia is considered a medical emergency, and it can lead to severe complications for both the mother and the baby if not promptly treated. The exact cause of eclampsia is not fully understood, but it is thought to be related to problems with the blood vessels that supply the placenta.

Symptoms of eclampsia include high blood pressure, severe headaches, visual disturbances, nausea and vomiting, and sudden weight gain. If left untreated, eclampsia can lead to serious complications such as brain damage, stroke, kidney failure, and even death for the mother and the baby.

Treatment typically involves close monitoring of the mother and the baby, medication to control seizures and lower blood pressure, and delivery of the baby if necessary. In some cases, eclampsia may occur after the baby has been delivered, in which case it is known as postpartum eclampsia.

Hyperparathyroidism is a condition in which the parathyroid glands produce excessive amounts of parathyroid hormone (PTH). There are four small parathyroid glands located in the neck, near or within the thyroid gland. They release PTH into the bloodstream to help regulate the levels of calcium and phosphorus in the body.

In hyperparathyroidism, overproduction of PTH can lead to an imbalance in these minerals, causing high blood calcium levels (hypercalcemia) and low phosphate levels (hypophosphatemia). This can result in various symptoms such as fatigue, weakness, bone pain, kidney stones, and cognitive issues.

There are two types of hyperparathyroidism: primary and secondary. Primary hyperparathyroidism occurs when there is a problem with one or more of the parathyroid glands, causing them to become overactive and produce too much PTH. Secondary hyperparathyroidism develops as a response to low calcium levels in the body due to conditions like vitamin D deficiency, chronic kidney disease, or malabsorption syndromes.

Treatment for hyperparathyroidism depends on the underlying cause and severity of symptoms. In primary hyperparathyroidism, surgery to remove the overactive parathyroid gland(s) is often recommended. For secondary hyperparathyroidism, treating the underlying condition and managing calcium levels with medications or dietary changes may be sufficient.

Muscular diseases, also known as myopathies, refer to a group of conditions that affect the functionality and health of muscle tissue. These diseases can be inherited or acquired and may result from inflammation, infection, injury, or degenerative processes. They can cause symptoms such as weakness, stiffness, cramping, spasms, wasting, and loss of muscle function.

Examples of muscular diseases include:

1. Duchenne Muscular Dystrophy (DMD): A genetic disorder that results in progressive muscle weakness and degeneration due to a lack of dystrophin protein.
2. Myasthenia Gravis: An autoimmune disease that causes muscle weakness and fatigue, typically affecting the eyes and face, throat, and limbs.
3. Inclusion Body Myositis (IBM): A progressive muscle disorder characterized by muscle inflammation and wasting, typically affecting older adults.
4. Polymyositis: An inflammatory myopathy that causes muscle weakness and inflammation throughout the body.
5. Metabolic Myopathies: A group of inherited disorders that affect muscle metabolism, leading to exercise intolerance, muscle weakness, and other symptoms.
6. Muscular Dystonias: Involuntary muscle contractions and spasms that can cause abnormal postures or movements.

It is important to note that muscular diseases can have a significant impact on an individual's quality of life, mobility, and overall health. Proper diagnosis and treatment are crucial for managing symptoms and improving outcomes.

Nephrolithiasis is a medical term that refers to the presence of stones or calculi in the kidney. These stones can form anywhere in the urinary tract, including the kidneys, ureters, bladder, and urethra. Nephrolithiasis is also commonly known as kidney stones.

Kidney stones are hard deposits made up of minerals and salts that crystallize in the urine. They can vary in size from tiny sand-like particles to larger pebble or even golf ball-sized masses. Kidney stones can cause pain, bleeding, and infection if they block the flow of urine through the urinary tract.

The formation of kidney stones is often associated with a variety of factors such as dehydration, high levels of calcium, oxalate, or uric acid in the urine, family history, obesity, and certain medical conditions like gout or inflammatory bowel disease. Treatment for nephrolithiasis depends on the size and location of the stone, as well as the severity of symptoms. Small stones may pass spontaneously with increased fluid intake, while larger stones may require medication, shock wave lithotripsy, or surgical removal.

The parathyroid glands are four small endocrine glands located in the neck, usually near or behind the thyroid gland. They secrete parathyroid hormone (PTH), which plays a critical role in regulating calcium and phosphate levels in the blood and bones. PTH helps maintain the balance of these minerals by increasing the absorption of calcium from food in the intestines, promoting reabsorption of calcium in the kidneys, and stimulating the release of calcium from bones when needed. Additionally, PTH decreases the excretion of calcium through urine and reduces phosphate reabsorption in the kidneys, leading to increased phosphate excretion. Disorders of the parathyroid glands can result in conditions such as hyperparathyroidism (overactive glands) or hypoparathyroidism (underactive glands), which can have significant impacts on calcium and phosphate homeostasis and overall health.

Acidosis is a medical condition that occurs when there is an excess accumulation of acid in the body or when the body loses its ability to effectively regulate the pH level of the blood. The normal pH range of the blood is slightly alkaline, between 7.35 and 7.45. When the pH falls below 7.35, it is called acidosis.

Acidosis can be caused by various factors, including impaired kidney function, respiratory problems, diabetes, severe dehydration, alcoholism, and certain medications or toxins. There are two main types of acidosis: metabolic acidosis and respiratory acidosis.

Metabolic acidosis occurs when the body produces too much acid or is unable to eliminate it effectively. This can be caused by conditions such as diabetic ketoacidosis, lactic acidosis, kidney failure, and ingestion of certain toxins.

Respiratory acidosis, on the other hand, occurs when the lungs are unable to remove enough carbon dioxide from the body, leading to an accumulation of acid. This can be caused by conditions such as chronic obstructive pulmonary disease (COPD), asthma, and sedative overdose.

Symptoms of acidosis may include fatigue, shortness of breath, confusion, headache, rapid heartbeat, and in severe cases, coma or even death. Treatment for acidosis depends on the underlying cause and may include medications, oxygen therapy, fluid replacement, and dialysis.

I'm sorry for any confusion, but "opossums" are not a medical term or a medical condition. Opossums are actually marsupials (pouched mammals) that are native to the Americas. They are often known for their "playing dead" behavior as a defense mechanism when threatened. If you have any questions about medical terminology or health-related topics, I'd be happy to help with those!

Physiologic calcification is the normal deposit of calcium salts in body tissues and organs. It is a natural process that occurs as part of the growth and development of the human body, as well as during the repair and remodeling of tissues.

Calcium is an essential mineral that plays a critical role in many bodily functions, including bone formation, muscle contraction, nerve impulse transmission, and blood clotting. In order to maintain proper levels of calcium in the body, excess calcium that is not needed for these functions may be deposited in various tissues as a normal part of the aging process.

Physiologic calcification typically occurs in areas such as the walls of blood vessels, the lungs, and the heart valves. While these calcifications are generally harmless, they can sometimes lead to complications, particularly if they occur in large amounts or in sensitive areas. For example, calcification of the coronary arteries can increase the risk of heart disease, while calcification of the lung tissue can cause respiratory symptoms.

It is important to note that pathologic calcification, on the other hand, refers to the abnormal deposit of calcium salts in tissues and organs, which can be caused by various medical conditions such as chronic kidney disease, hyperparathyroidism, and certain infections. Pathologic calcification is not a normal process and can lead to serious health complications if left untreated.

A kidney, in medical terms, is one of two bean-shaped organs located in the lower back region of the body. They are essential for maintaining homeostasis within the body by performing several crucial functions such as:

1. Regulation of water and electrolyte balance: Kidneys help regulate the amount of water and various electrolytes like sodium, potassium, and calcium in the bloodstream to maintain a stable internal environment.

2. Excretion of waste products: They filter waste products from the blood, including urea (a byproduct of protein metabolism), creatinine (a breakdown product of muscle tissue), and other harmful substances that result from normal cellular functions or external sources like medications and toxins.

3. Endocrine function: Kidneys produce several hormones with important roles in the body, such as erythropoietin (stimulates red blood cell production), renin (regulates blood pressure), and calcitriol (activated form of vitamin D that helps regulate calcium homeostasis).

4. pH balance regulation: Kidneys maintain the proper acid-base balance in the body by excreting either hydrogen ions or bicarbonate ions, depending on whether the blood is too acidic or too alkaline.

5. Blood pressure control: The kidneys play a significant role in regulating blood pressure through the renin-angiotensin-aldosterone system (RAAS), which constricts blood vessels and promotes sodium and water retention to increase blood volume and, consequently, blood pressure.

Anatomically, each kidney is approximately 10-12 cm long, 5-7 cm wide, and 3 cm thick, with a weight of about 120-170 grams. They are surrounded by a protective layer of fat and connected to the urinary system through the renal pelvis, ureters, bladder, and urethra.

Total Parenteral Nutrition (TPN) is a medical term used to describe a specialized nutritional support system that is delivered through a vein (intravenously). It provides all the necessary nutrients that a patient needs, such as carbohydrates, proteins, fats, vitamins, and minerals. TPN is typically used when a patient cannot eat or digest food through their gastrointestinal tract for various reasons, such as severe malabsorption, intestinal obstruction, or inflammatory bowel disease. The term "total" indicates that the nutritional support is complete and meets all of the patient's nutritional needs.

Calcium is an essential mineral that is vital for various physiological processes in the human body. The medical definition of calcium is as follows:

Calcium (Ca2+) is a crucial cation and the most abundant mineral in the human body, with approximately 99% of it found in bones and teeth. It plays a vital role in maintaining structural integrity, nerve impulse transmission, muscle contraction, hormonal secretion, blood coagulation, and enzyme activation.

Calcium homeostasis is tightly regulated through the interplay of several hormones, including parathyroid hormone (PTH), calcitonin, and vitamin D. Dietary calcium intake, absorption, and excretion are also critical factors in maintaining optimal calcium levels in the body.

Hypocalcemia refers to low serum calcium levels, while hypercalcemia indicates high serum calcium levels. Both conditions can have detrimental effects on various organ systems and require medical intervention to correct.

Cardiac monitoring is also advised.[citation needed] X-linked hypophosphatemia "Hypophosphatemia". Merck Manuals Professional ... Hypophosphatemia is an electrolyte disorder in which there is a low level of phosphate in the blood. Symptoms may include ... Hypophosphatemia occurs in about 2% of people within hospital and 70% of people in the intensive care unit (ICU). Muscle ... Primary hypophosphatemia is the most common cause of non-nutritional rickets. Laboratory findings include low-normal serum ...
... (XLH) is an X-linked dominant form of rickets (or osteomalacia) that differs from most cases of ... X-linked hypophosphatemia may be lumped in with autosomal dominant hypophosphatemic rickets under general terms such as ... 00754 at CHORUS Hypophosphatemic rickets; XLH; Hypophosphatemia, vitamin D-resistant rickets at NIH's Office of Rare Diseases ( ... Autosomal dominant hypophosphatemic rickets Hypophosphatemia Tumor-induced osteomalacia Online Mendelian Inheritance in Man ( ...
Ruppe MD (1993). "X-Linked Hypophosphatemia". In Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, Gripp KW, Amemiya A (eds ... X-linked hypophosphatemia Rickets Vitamin D deficiency Laroche M, Boyer JF (October 2005). "Phosphate diabetes, tubular ... August 2009). "FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF ... July 2019). "The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey". Journal of the ...
ALPL Hypophosphatemia, X-linked; 307800; PHEX Hypophosphatemic rickets with hypercalciuria; 241530; SLC34A3 Hypophosphatemic ...
Marik, Paul E. (1996-10-01). "Refeeding Hypophosphatemia in Critically Ill Patients in an Intensive Care Unit". Archives of ... The most serious and common electrolyte abnormality is hypophosphatemia, although sodium abnormalities are common as well. It ... Incidence of refeeding syndrome is high, with one prospective cohort study showing 34% of ICU experienced hypophosphatemia soon ... "Hyperalimentation, Hypophosphatemia and Coma". Anesthesiology. 38 (3): 308. March 1973. doi:10.1097/00000542-197303000-00032. ...
... ation is used to treat hypophosphatemia. Most hypophosphatemia occurs when phosphate leaves the circulation ...
Hypophosphatemia is diagnosed by blood phosphorus levels. Cushing syndrome is very rare, and is typically diagnosed clinically ... Hypophosphatemia due to increased fibroblast growth factor 23 production may lead to rickets, osteomalacia, and worsening ... Untreated hyperthyroidism and hypophosphatemia increases the risk of fractures and skeletal deformities. For treatment of ... Oral phosphate and calcitriol may be given for treatment of hypophosphatemia. For growth hormone excess, treatment with ...
FGF23 is associated with at least 7 non-nutritional diseases of hypophosphatemia: aside from autosomal dominant ... Strewler GJ (May 2001). "FGF23, hypophosphatemia, and rickets: has phosphatonin been found?". Proceedings of the National ... "FGF23 and its role in X-linked hypophosphatemia-related morbidity". Orphanet Journal of Rare Diseases. 14 (1): 58. doi:10.1186/ ... hypophosphatemic rickets, X-linked hypophosphatemia, autosomal recessive hypophosphatemic rickets type 1, 2, and 3, Tumor- ...
"Soft and weak bones? Have you heard of X-linked hypophosphatemia (XLH)? Learn more about this disease and its symptoms". ... Without enough phosphorus bones and teeth soften, and muscles become weak, as in X-linked hypophosphatemia. Osteocytes ...
Phosphate deficiency is a problem known as hypophosphatemia. A typical 70 kg human contains 480 g of phosphorus. Arsenic ...
In the absence of functional PHEX in the mouse model (Hyp) of X-linked hypophosphatemia (XLH), and in human XLH where PHEX ... February 2017). "Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia". Bone. 95: 151-161. doi:10.1016/j ... February 2017). "Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia". Bone. 95: 151-161. doi:10.1016/j ... Mutation of PHEX leads to X-linked hypophosphatemia. GRCh38: Ensembl release 89: ENSG00000102174 - Ensembl, May 2017 GRCm38: ...
In medicine, monopotassium phosphate is used for phosphate substitution in hypophosphatemia. A large KDP crystal, used in the ... Gaasbeek, André; Meinders, A. Edo (October 2005). "Hypophosphatemia: an update on its etiology and treatment". The American ...
Burosumab (KRN-23; brand name Crysvita) was approved in 2018 by the FDA to treat X-linked hypophosphatemia. In 2020 the drug ... "Burosumab Therapy in Children with X-Linked Hypophosphatemia". The New England Journal of Medicine. 378 (21): 1987-1998. doi: ...
Patients with hypophosphatemia may develop rickets/osteomalacia, increased fractures, and bone pain. Fibrous dysplasia is a ... Untreated hypophosphatemia increases bone pain and risk of fractures. Cherubism Dysplasia McCune-Albright syndrome Tafti, ... and hypophosphatemia". American Journal of Medical Genetics (4 ed.). 14 (4): 725-35. doi:10.1002/ajmg.1320140414. PMID 6846403 ...
... therapy is contraindicated in hypophosphatemia or bowel obstruction. In hypophosphatemia, sevelamer could exacerbate ...
Page 6 O'Connor G, Nicholls D (June 2013). "Refeeding hypophosphatemia in adolescents with anorexia nervosa: a systematic ...
Hypocalcemia and hypophosphatemia (instances that stimulate kidney proximal tubule cells to produce calcitriol (1α,25- ... February 2017). "Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia". Bone. 95: 151-161. doi:10.1016/j ... in X-linked hypophosphatemia, XLH) lead to altered processing of OPN such that inhibitory OPN cannot be degraded and ... the murine model of X-linked hypophosphatemia". Journal of Bone and Mineral Research. 28 (3): 688-699. doi:10.1002/jbmr.1766. ...
Diagnosis of osteosarcoma, ameloblastoma, renal osteodystrophy affecting jaws and hypophosphatemia. Diagnosis, and pre- and ...
... and X-linked hypophosphatemia (XLH). The most common cause of osteomalacia is a deficiency of vitamin D, which is normally ... the murine model of X-linked hypophosphatemia". Journal of Bone and Mineral Research. 28 (3): 688-99. doi:10.1002/jbmr.1766. ... "Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia". Bone. 95: 151-161. doi:10.1016/j.bone.2016.11.019 ... and relationship to hypophosphatasia and X-linked hypophosphatemia". Periodontology 2000. 63 (1): 102-22. doi:10.1111/prd.12029 ...
ISBN 978-1-4377-1753-2. Tenenhouse HS (February 1999). "X-linked hypophosphataemia: a homologous disorder in humans and mice". ... Mutations in this gene are associated with hypophosphatemia nephrolithiasis/osteoporosis 1. Renal physiology Cotransporter Co- ...
They cause hypophosphatemia, hypocalcemia, low vitamin D levels, and increased parathyroid hormone. Anticonvulsants also ...
Polderman KH, Peerdeman SM, Girbes AR (May 2001). "Hypophosphatemia and hypomagnesemia induced by cooling in patients with ... and hypophosphatemia, as well as hypovolemia. The earliest rationale for the effects of hypothermia as a neuroprotectant ...
Other than those listed below, common complications of TPN include hypophosphatemia, hypokalemia, hyperglycemia, hypercapnia, ... Metabolic complications include the refeeding syndrome characterised by hypokalemia, hypophosphatemia and hypomagnesemia. ...
For example, genetic or hereditary hypophosphatemia may cause the metabolic bone disorder osteomalacia. Although there is ...
Skeletal abnormalities may include dental irregularities, scoliosis, vitamin D-resistant rickets and hypophosphatemia. ...
"FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia". U.S. Food and Drug Administration. ...
The proximal renal tubular dysfunction causes hypophosphatemia, leading to muscle weakness and sometimes coma. Hyperchloremia ...
"FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia" (Press release). U.S. Food and Drug ... Due to the excess activity of FGF23, phosphate levels in the blood are abnormally low (hypophosphatemia), which affects the ... "Burosumab (KRN23) for X-Linked Hypophosphatemia (XLH)" (PDF). n.d. Archived from the original (PDF) on 18 April 2018. Retrieved ... "1 Recommendations , Burosumab for treating X-linked hypophosphataemia in children and young people. Guidance NICE". www.nice. ...
Despite cautious management, he had hypophosphatemia and fluid retention, important elements of the refeeding syndrome." On May ...
Causes may include mitochondrial disease (particularly MELAS) or chronic hypophosphatemia, as may occur in cystinosis. ...
Cardiac monitoring is also advised.[citation needed] X-linked hypophosphatemia "Hypophosphatemia". Merck Manuals Professional ... Hypophosphatemia is an electrolyte disorder in which there is a low level of phosphate in the blood. Symptoms may include ... Hypophosphatemia occurs in about 2% of people within hospital and 70% of people in the intensive care unit (ICU). Muscle ... Primary hypophosphatemia is the most common cause of non-nutritional rickets. Laboratory findings include low-normal serum ...
Hypophosphatemia is a low level of phosphorus in the blood. ... Hypophosphatemia is a low level of phosphorus in the blood. ...
Hypophosphatemia is defined as a phosphate level of less than 2.5 mg/dL (0. ... Hypophosphatemia has been reported in up to 15% of geriatric patients undergoing refeeding. [30] Hypophosphatemia has also been ... Hypophosphatemia can occur in persons of any age. Acquired hypophosphatemia tends to occur in late adolescence to adulthood. ... 25] Hypophosphatemia in this setting is associated with a favorable prognosis. Hypophosphatemia is also seen in approximately ...
WebMD provides a list of natural remedies used to treat Hypophosphatemia. ... Considering taking a vitamin or supplement to treat Hypophosphatemia? Below is a list of common natural remedies used to treat ... or reduce the symptoms of Hypophosphatemia. Follow the links to read common uses, side effects, dosage details and read user ...
Learn about the veterinary topic of Hypophosphatemia in Animals. Find specific details on this topic and related topics from ... The clinical relevance of hypophosphatemia is poorly understood, because clinical signs associated with hypophosphatemia are ... Etiology and Pathogenesis of Hypophosphatemia in Animals The most common cause of chronic phosphorus deficiency is inadequate ... Hypophosphatemia in Animals By Walter Grünberg , DVM, PhD, DECAR, DECBHM, Faculty of Veterinary Medicine, Justus-Liebig- ...
Further investigations revealed no cause for his severe hypophosphataemia and repeat bloods in clinic follow-up showed a normal ... Laboratory investigations revealed severe hypophosphataemia (phosphate 0.19 mmol/L) and no other electrolyte abnormality. He ...
Other names Hypophosphatemias, Familial; Familial Hypophosphatemias; Phosphaturia; Phosphate Diabetes; Hyperphosphaturia; ... This leads to phosphaturia, HYPOPHOSPHATEMIA, and disturbances of cellular and organ functions such as those in X-LINKED ... Familial Hypophosphatemia; Diabetes, Phosphate To share this definition, click "text" (Facebook, Twitter) or "link" (blog, mail ...
Severe hypercalcaemia and hypophosphataemia with an optimised preterm parenteral nutrition formulation in two epochs of ... Severe hypercalcaemia and hypophosphataemia with an optimised preterm parenteral nutrition formulation in two epochs of ... hypophosphataemia (PO4,1.5 mmol/L), and hypokalaemia (K+ ,3.5 mmol/L) within the first postnatal week. ... and there were fewer cases of hypophosphataemia (17/49, 35% vs 31/51, 61%, p value=0.009) and hypokalaemia (12/49, 25% vs 23/51 ...
Hypophosphatemia - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the MSD Manuals - Medical ... Symptoms and Signs of Hypophosphatemia Although hypophosphatemia usually is asymptomatic, anorexia, muscle weakness, and ... Hypophosphatemia is a serum phosphate concentration < 2.5 mg/dL (0.81 mmol/L). Causes include alcohol use disorder, burns, ... Hypophosphatemia occurs in 2% of patients who are hospitalized but is more prevalent in certain populations (eg, it occurs in ...
Differentiating Hypophosphatemia from other Diseases. Epidemiology and Demographics. Risk Factors. Natural History, ... Synonyms and keywords: Hypophosphataemia; phosphate levels low (plasma or serum). Overview. Historical Perspective. ... Retrieved from "https://www.wikidoc.org/index.php?title=Hypophosphatemia&oldid=851105" ...
Hypophosphatemia answers are found in the Diagnosaurus powered by Unbound Medicine. Available for iPhone, iPad, Android, and ... Medicine Central, im.unboundmedicine.com/medicine/view/Diagnosaurus/114280/all/Hypophosphatemia. Zeiger RFR. Hypophosphatemia. ... Zeiger, Roni F.. "Hypophosphatemia." Diagnosaurus, 4th ed., McGraw-Hill Education, 2014. ... https://im.unboundmedicine.com/medicine/view/Diagnosaurus/114280/all/Hypophosphatemia. Zeiger RFR. Hypophosphatemia [Internet ...
... , ... Sclerostin Antibody Rescues Hypophosphatemia And Increases Bone Mass In Hyp Mouse Model. ...
Marvin V, Brown D, Portlock J, Livingstone C. Factors contributing to the development of hypophosphataemia when refeeding using ... Method: Seventy patients (cases) with refeeding hypophosphataemia were matched with controls who had not experienced a fall in ... Method: Seventy patients (cases) with refeeding hypophosphataemia were matched with controls who had not experienced a fall in ... Method: Seventy patients (cases) with refeeding hypophosphataemia were matched with controls who had not experienced a fall in ...
Familial hypophosphatemia. Several different familial and acquired conditions may lead to hypophosphatemia in children. In ... As hypophosphatemia is usually clinically evident at a later age, infantile skull defects are not apparent. Because calcium ... Levels of 1,25(OH)2 vitamin D are actually normal in these patients, owing to an abnormal response to hypophosphatemia, in ... It is indicated for X-linked hypophosphatemia in adult and pediatric patients aged 6 months or older. It is also approved for ...
Recent studies suggest Injectafer may cause severe hypophosphatemia, a dangerous condition resulting from low levels of ... of patients treated with ferric carboxymaltose experienced hypophosphatemia, while 32% developed severe hypophosphatemia. ... Injectafer and Severe Hypophosphatemia. As early as 2013, research indicated that ferric carboxmaltose could lower phosphorus ... However, recent studies suggest Injectafer is more likely to cause severe hypophosphatemia (dangerously low levels of ...
... Progress in Rare Diseases: Coming to a better understanding of X-linked hypophosphatemia (XLH). 7 May ...
encoded search term (Hypophosphatemia in Emergency Medicine) and Hypophosphatemia in Emergency Medicine What to Read Next on ... Hypophosphatemia in Emergency Medicine Differential Diagnoses. Updated: Dec 22, 2014 * Author: Luda Khait, MD, MS; Chief Editor ... Treatment of hypophosphatemia using a protocol based on patient weight and serum phosphorus level in a surgical intensive care ... Tejeda A, Saffarian N, Uday K, Dave M. Hypophosphatemia in end stage renal disease. Nephron. 1996. 73(4):674-8. [QxMD MEDLINE ...
Dive into the research topics of Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney ... Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. ...
Melissa Thompson-Bastin discusses managing phosphate levels and preventing hypophosphatemia in CRRT, as well as how and when to ... Melissa Thompson-Bastin discusses managing phosphate levels and preventing hypophosphatemia in CRRT, as well as how and when to ...
... observational Registry of patients with X-Linked hypophosphatemia (XLH). The main objective of this XLH Registry is to collect ... observational Registry of patients with X-Linked hypophosphatemia (XLH). The objectives of this XLH Registry is to collect ...
Finding an appropriate instrument for data collection about burden on carers of people with X-Linked Hypophosphataemia: a carer ... Finding an appropriate instrument for data collection about burden on carers of people with X-Linked Hypophosphataemia: a carer ...
X-LINKED HYPOPHOSPHATAEMIA: BURDEN OF DISEASE USING UK PRIMARY CARE DATA Javaid MK., Delmestri A., Shaw N., Prieto-Alhambra D ...
Kleen enema Hypophosphatemia correction in hemodialysis patients. Authors. * Dr Kunwer Naveed Liaqat National Hospital ... hypophosphatemia, hemodialysis, malnourishment Abstract. Dialysis fluid (Dialysate) is a solution consisting of inorganic ions ...
Evidence for mineral changes due to hypophosphatemia. The X-ray diffraction data show that bone mineral in the virgin HYP mouse ... At five months of age, the mice are skeletally mature and the HYP mice display the effects of hypophosphatemia. Thus, five- ... Evidence for changes in bone mineral characteristics due to hypophosphatemia. HYP mice have been shown to have an impaired ... During this stage HYP mice do not display any metabolic or skeletal phenotypes associated with hypophosphatemia, as all mineral ...
Critical Hypophosphatemia Severe hypophosphatemia may develop secondary to a refeeding syndrome that leads to critical ... Consequently, extreme hypophosphatemia can limit glycolysis and ATP generation, which is the sole source of energy in these ... In nontreated cats, hemolytic anemia develops ~24-48 hours after onset of extreme hypophosphatemia (, 2.0 mEq/L; see feline ... Increased risk for clinical hypophosphatemia also exists for cats with ketoacidotic diabetes mellitus because of their ...
... it remains uncertain when and how to correct hypophosphatemia. Outcome: in some studies, hypophosphatemia was associated with ... Incidence: hypophosphatemia is frequently encountered in the intensive care unit; and critically ill patients are at increased ... Treatment: hypophosphatemia is generally corrected when it is symptomatic or severe. However, although multiple studies confirm ... Symptoms: hypophosphatemia may lead to a multitude of symptoms, including cardiac and respiratory failure. ...
Szczesny, Pawel and Poznański, Jarosław and Paczek, Leszek and Zielenkiewicz, Piotr (2014) Hypophosphatemia and sudden infant ... In their recent letter Van Kempen and co-workers presented an intriguing hypothesis linking hypophosphatemia and sudden infant ...
X linked hypophosphataemia (XLH) is a rare condition with numerous musculoskeletal complications. It may mimic other more ... X linked hypophosphataemia (XLH) is a rare condition with numerous musculoskeletal complications. It may mimic other more ...
Royces earliest memory of being treated for X-linked hypophosphataemia (XLH) was the phosphate supplement he had to drink five ...
... hypophosphatemia) and in the urine, and to acidify the urine. Common side effects include nausea, vomiting, stomach pain, gas ( ... What Is the Treatment for Hypophosphatemia (Low Phosphate)?. Treatment of hypophosphatemia or low serum phosphate levels can ... hypophosphatemia) and in the urine, and to acidify the urine. Potassium phosphate is a combination salt of potassium and ... hypophosphatemia) and in the urine, and to acidify the urine. Potassium phosphate is a combination salt of potassium and ...
  • Burosumab, an IgG1 monoclonal antibody that binds excess fibroblast growth factor 23 (FGF23), is approved for treatment of X-linked hypophosphatemia and of FGF23-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized, in adults and pediatric patients aged 2 years or older. (medscape.com)
  • Oral Phosphate Supplementation Corrects Hypophosphatemia and Normalizes Plasma FGF23 and 25-Hydroxyvitamin D3 Levels in Women with Chronic Metabolic Acidosis. (medscape.com)
  • Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. (bvsalud.org)
  • In children with XLH, excess FGF23 causes hypophosphatemia with consequent rickets, skeletal deformities, and impaired growth and mobility. (eurospe.org)
  • Another important novel finding was made in 2000, when bone-derived hormone Fibroblast Growth Factor-23 (FGF23) was found to cause autosomal dominant hypophosphataemic rickets (ADHR), which provided the underlying mechanism for the previously unknown "phosphaturic factor" causing hypophosphataemia ( 2 , 3 ). (frontiersin.org)
  • X-linked hypophosphatemia (XLH) is a rare, inherited, chronic progressive musculoskeletal disorder characterized by renal phosphate wasting caused by excess phosphaturic hormone fibroblast growth factor 23 (FGF23) production. (medscape.com)
  • Method: Seventy patients (cases) with refeeding hypophosphataemia were matched with controls who had not experienced a fall in phosphate levels when commenced on PN. (port.ac.uk)
  • Dr. Melissa Thompson-Bastin discusses managing phosphate levels and preventing hypophosphatemia in CRRT, as well as how and when to implement Baxter's renal replacement solutions.Dr. Melissa Thompson-Bastin discusses managing phosphate levels and preventing hypophosphatemia in CRRT, as well as how and when to implement Baxter's renal replacement solutions. (baxter.com)
  • Laboratory investigations revealed severe hypophosphataemia (phosphate 0.19 mmol/L) and no other electrolyte abnormality. (bmj.com)
  • Further investigations revealed no cause for his severe hypophosphataemia and repeat bloods in clinic follow-up showed a normal phosphate level. (bmj.com)
  • Refeeding encephalopathy in a patient with severe hypophosphataemia and hyperammonaemia. (medscape.com)
  • Sebastian S, Clarence D, Newson C. Severe hypophosphataemia mimicking Guillain-Barré syndrome. (medscape.com)
  • Hypophosphatemia is defined as a serum phosphate level of less than 2.5 mg/dL (0.8 mmol/L) in adults. (medscape.com)
  • nadir plasma phosphate concentrations were higher (means: 1.54 mmol/L vs 1.32 mmol/L, p value=0.006), and there were fewer cases of hypophosphataemia (17/49, 35% vs 31/51, 61%, p value=0.009) and hypokalaemia (12/49, 25% vs 23/51, 45%, p value=0.03). (bmj.com)
  • Hypophosphatemia is a serum phosphate concentration 2.5 mg/dL (0.81 mmol/L). Causes include alcohol use disorder, burns, starvation, and diuretic use. (msdmanuals.com)
  • Primary hypophosphatemia is the most common cause of non-nutritional rickets. (wikipedia.org)
  • The clinical relevance of hypophosphatemia is poorly understood, because clinical signs associated with hypophosphatemia are not well defined. (merckvetmanual.com)
  • Among other things, the agency noted that patients treated with ferric carboxymaltose experienced higher rates of death, hypophosphatemia, and other adverse events during clinical trials compared to patients treated with oral iron supplements. (rxinjuryhelp.com)
  • Based on clinical observation and laboratory findings the case was diagnosed as hypophosphatemia .The animal was treated with inj. (thepharmajournal.com)
  • citation needed] Other rarer causes include: Certain blood cancers such as lymphoma or leukemia Hereditary causes Liver failure Tumor-induced osteomalacia[citation needed] Hypophosphatemia is caused by the following three mechanisms: Inadequate intake (often unmasked in refeeding after long-term low phosphate intake) Increased excretion (e.g. in hyperparathyroidism, hypophosphatemic rickets) Shift of phosphorus from the extracellular to the intracellular space. (wikipedia.org)
  • Tumor-induced osteomalacia (TIO) is a rare, acquired paraneoplastic disorder characterized by a renal phosphate leak leading to hypophosphatemia and deranged bone turnover. (hindawi.com)
  • Hypophosphatemia without phosphorus depletion may occur after oral or parenteral carbohydrate administration and after parenteral insulin administration as a result of increased cellular phosphorus uptake in combination with glucose. (merckvetmanual.com)
  • In most patients with severe hypophosphatemia, both depletion of total body phosphorus stores and redistribution of phosphate to the intracellular space are found. (biomedcentral.com)
  • Transient but pronounced hypophosphatemia, however, was also shown to occur in previously mastectomized periparturient cows, indicating that other mechanisms, such as depressed feed intake around calving, decreased GI motility related to the concomitantly occurring hypocalcemia, or hormonally driven shifts of inorganic phosphorus toward the intracellular space are likely to be at least equally important causal factors. (merckvetmanual.com)
  • and critically ill patients are at increased risk for developing hypophosphatemia due to the presence of multiple causal factors. (biomedcentral.com)
  • Taylor BE, Huey WY, Buchman TG, Boyle WA, Coopersmith CM. Treatment of hypophosphatemia using a protocol based on patient weight and serum phosphorus level in a surgical intensive care unit. (medscape.com)
  • Hypophosphatemia is a low level of phosphorus in the blood. (medlineplus.gov)
  • On the mechanism of hypophosphatemia during acute hyperventilation: evidence for increased muscle glycolysis. (medscape.com)
  • Chronic hypophosphatemia usually is the result of decreased renal phosphate reabsorption. (msdmanuals.com)
  • The renal phosphate leak manifests itself in hypophosphatemia. (hindawi.com)
  • Aim: To identify individual attributes or risk factors which predispose to the development of refeeding hypophosphataemia in patients on parenteral nutrition (PN).Setting: The Royal Surrey County Hospital (RSCH) a 530 bed, non-teaching Trust with a cancer centre, medical and surgical inpatients and intensive care unit (ICU). (port.ac.uk)
  • Hypophosphatemia is an electrolyte disorder in which there is a low level of phosphate in the blood. (wikipedia.org)
  • Studies should focus on the association between hypophosphatemia and morbidity and/or mortality, as well as the effect of correction of this electrolyte disorder. (biomedcentral.com)
  • Hypophosphatemia is one of those frequently encountered electrolyte disorders, for which many causative factors are present in critically ill patients. (biomedcentral.com)
  • Hypophosphatemia is a common finding in horses with chronic renal failure. (merckvetmanual.com)
  • Notably, articles on chronic hypophosphatemia (for example, hereditary hypophosphatemic syndromes) were excluded. (biomedcentral.com)
  • Most patients with hypophosphatemia are asymptomatic. (medscape.com)
  • Occasionally, patients with mild hypophosphatemia may complain of weakness. (medscape.com)
  • Conclusion: Patients with a high NRS score prior to commencing nutrition support may be more at risk than others of refeeding hypophosphataemia. (port.ac.uk)
  • Camp MA, Allon M. Severe hypophosphatemia in hospitalized patients. (medscape.com)
  • Alterations of red-cell glycolytic intermediates and oxygen transport as a consequence of hypophosphatemia in patients receiving intravenous hyperalimentation. (medscape.com)
  • Brief Summary This is an international, multicentre, prospective, non-interventional, observational Registry of patients with X-Linked hypophosphatemia (XLH). (cardiff.ac.uk)
  • Kleen enema Hypophosphatemia correction in hemodialysis patients. (com.pk)
  • Currently no evidence-based guideline exists for the approach to hypophosphatemia in critically ill patients. (biomedcentral.com)
  • We performed a narrative review of the medical literature to identify the incidence, symptoms, and treatment of hypophosphatemia in critically ill patients. (biomedcentral.com)
  • a paucity of randomized controlled evidence exists for whether correction of hypophosphatemia improves the outcome in critically ill patients. (biomedcentral.com)
  • Additional studies addressing the current approach to hypophosphatemia in critically ill patients are required. (biomedcentral.com)
  • It is uncertain when and how to correct hypophosphatemia, and whether correction affects outcome in critically ill patients. (biomedcentral.com)
  • We searched the literature on hypophosphatemia in ICU patients to identify the incidence, symptoms, and treatment of hypophosphatemia. (biomedcentral.com)
  • Intravenous iron (usually for anemia) may cause hypophosphatemia. (wikipedia.org)
  • However, although multiple studies confirm the efficacy and safety of intravenous phosphate administration, it remains uncertain when and how to correct hypophosphatemia. (biomedcentral.com)
  • Hypophosphatemia Associated with Intravenous Ferric Carboxymaltose Complicated by Multiple Insufficiency Fractures. (upenn.edu)
  • PO 4 molar ratio of 1.3-1.5:1 to a ratio of 1.0:1 was associated with a lower incidence and severity of hypophosphataemia and hypercalcaemia. (bmj.com)
  • X linked hypophosphataemia (XLH) is a rare condition with numerous musculoskeletal complications. (ox.ac.uk)
  • Specifically, we searched for answers to the questions whether correction of hypophosphatemia is associated with improved outcome, and whether a certain treatment strategy is superior. (biomedcentral.com)
  • The medications are hydrocortisone granules in capsules for opening ( Alkindi , Diurnal) for the treatment of primary adrenal insufficiency in infants, children, and adolescents, and burosumab ( Crysvita , Kyowa Hakko Kirin/Ultragenyx Pharmaceutical) for the treatment of X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. (medscape.com)
  • In practice, however, it is common to consider hypophosphatemia as a synonym for phosphorus deficiency, which is incorrect and potentially misleading, because blood phosphate concentration is a poor surrogate marker for the phosphorous level in the body. (merckvetmanual.com)
  • However, recent studies suggest Injectafer is more likely to cause severe hypophosphatemia (dangerously low levels of phosphorous in the blood) compared to other injectable iron supplements. (rxinjuryhelp.com)
  • Considering taking a vitamin or supplement to treat Hypophosphatemia? (webmd.com)
  • Royce's earliest memory of being treated for X-linked hypophosphataemia (XLH) was the phosphate supplement he had to drink five times every day. (xlhlink.asia)
  • In addition, alcohol treatment is associated with refeeding, which further depletes phosphate, and the stress of alcohol withdrawal may create respiratory alkalosis, which exacerbates hypophosphatemia (see above). (wikipedia.org)
  • Symptoms: hypophosphatemia may lead to a multitude of symptoms, including cardiac and respiratory failure. (biomedcentral.com)
  • Hypophosphatemia occurs in about 2% of people within hospital and 70% of people in the intensive care unit (ICU). (wikipedia.org)
  • Below is a list of common natural remedies used to treat or reduce the symptoms of Hypophosphatemia. (webmd.com)
  • Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: R" by Eric T. Rush, Britt Johnson et al. (childrensmercy.org)
  • Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program. (childrensmercy.org)
  • Hypomagnesaemia prior to starting PN was non-significantly associated with refeeding hypophosphataemia. (port.ac.uk)
  • Liamis G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia: a review. (medscape.com)
  • Potassium phosphate/sodium phosphate is a medication used to correct lower than normal levels of phosphate in the blood (hypophosphatemia) and in the urine, and to acidify the urine. (medicinenet.com)
  • After resection of the tumor, hypophosphatemia and the increased levels of FGF-23 normalized within a few days. (hindawi.com)
  • Treatment: hypophosphatemia is generally corrected when it is symptomatic or severe. (biomedcentral.com)
  • Reversible depression of myocardial performance in hypophosphatemia. (medscape.com)
  • With a multi-disciplinary approach, Fact.MR elaborates an extensive analysis of the historical, current and future outlook of the global X-Linked Hypophosphatemia Market as well as the factors responsible for such a growth. (thecloudtribune.com)
  • Faroqui S, Levi M, Soleimani M, Amlal H. Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia. (medscape.com)
  • Your search for Hypophosphatemia returned 4 matches. (webmd.com)
  • Hypophosphatemia in the strict sense of the term refers to subnormal phosphorus concentrations in blood. (merckvetmanual.com)
  • In cattle, transient hypophosphatemia is commonly seen during the periparturient period, particularly in high-yielding dairy cows. (merckvetmanual.com)
  • Medicine Central , im.unboundmedicine.com/medicine/view/Diagnosaurus/114280/all/Hypophosphatemia. (unboundmedicine.com)
  • Acetazolamide-related Life-threatening Hypophosphatemia in a Glaucoma Patient. (medscape.com)
  • In our case, a 45-year-old male patient had multiple fractures accompanied by hypophosphatemia. (hindawi.com)